Exact Sciences is clearly amping up, hiring workers by the hundreds, building lab and office space, and pressing ahead with plans for cancer screening tests beyond Cologuard even as the competition mounts.
CEO and chairman Kevin Conroy has an aggressive vision for the Madison cancer screening product company and its potential impact on the health of Americans.
“I think that 10 years from now … we’ll be at the front lines of moving toward colon cancer eradication. That’s our goal,” Conroy said.
Conroy, 53, is convinced Cologuard — Exact’s home test kit that checks for blood and DNA biomarkers in stool — will be a key factor in accomplishing that.
“I think Cologuard and colonoscopy will be the two main ways (to screen for colorectal cancer). We’re on the path to do that, having screened more than 2 million people to date,” he said.
Exact plans to open its second Cologuard processing lab this month — a 113,000-square-foot clinical lab and 56,000-square-foot warehouse off Schroeder Road that eventually will raise the company’s processing capacity to 7 million samples a year.
;
